Should I Buy SRRK? SRRK 2026 Analysis

Should You Buy Scholar Rock Holding Corp (SRRK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

44.920

1 Day change

4.15%

52 Week Range

48.280

Analysis Updated At

2026/01/26

Scholar Rock Holding Corp (SRRK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is supported by positive analyst ratings, improving financial performance, and a resolution of manufacturing issues expected by Q1 2026. Despite the lack of recent trading signals and news, the technical indicators and options data suggest a neutral to slightly bullish sentiment, making it a reasonable entry point for long-term growth.

Technical Analysis

The stock's MACD is positive and contracting, RSI is neutral at 45.365, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are at S1: 41.691 and R1: 47.54, with the current pre-market price at $44.3, slightly above the pivot of 44.615.

Options Data

Neutral

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The open interest put-call ratio indicates a balanced sentiment, while the low option volume put-call ratio of 0.36 suggests more call activity, reflecting a slightly bullish sentiment.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have issued multiple buy ratings with price targets ranging from $42 to $60, citing a resolution of manufacturing issues and potential blockbuster sales for apitegromab. Financials show significant improvement in net income and EPS, and the biotech sector is expected to perform strongly in 2026.

Neutral/Negative Catalysts

No significant news or recent trading signals. The company is still awaiting commercial approval for apitegromab, and revenue remains at $0, indicating reliance on future product success.

Financial Performance

In Q3 2025, net income improved by 58.53% YoY to -$102.22 million, and EPS increased by 36.36% YoY to -$0.9. However, revenue and gross margin remain at $0, reflecting the pre-commercial stage of the company.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are overwhelmingly positive on SRRK, with recent buy ratings from Citi, UBS, Barclays, JPMorgan, and Wolfe Research. Price targets have been raised, with the highest target at $60, reflecting confidence in the company's future growth and resolution of manufacturing issues.

11 Analyst Rating

Wall Street analysts forecast SRRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRRK is 50 USD with a low forecast of 42 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 43.130

Low

Averages

High

Current: 43.130

Low

Averages

High

H.C. Wainwright

Andres Maldonado

Buy

maintain

$44 -> $58

AI Analysis

2026-01-26

New

Reason

H.C. Wainwright

Andres Maldonado

Price Target

$44 -> $58

AI Analysis

2026-01-26

New

maintain

Buy

Reason

H.C. Wainwright analyst Andres Maldonado raised the firm's price target on Scholar Rock to $58 from $44 and keeps a Buy rating on the shares. The firm has increased confidence in apitegromab's launch trajectory following key opinion leader feedback. Physicians consistently highlighted that additional FDA interactions and greater clarity around manufacturing remediation have reduced uncertainty, with several noting that Scholar Rock's parallel supply chain strategy meaningfully de-risks early launch execution, the analyst tells investors in a research note.

Citi

NULL -> Buy

initiated

$55

2026-01-09

Reason

Citi

Price Target

$55

2026-01-09

initiated

NULL -> Buy

Reason

Citi initiated coverage of Scholar Rock with a Buy rating and $55 price target. The firm believes concerns over the company's manufacturing on apitegromab in spinal muscular atrophy are overdone. Citi's checks indicate a near-term resolution of the manufacturing issues and potential application resubmission approval by Q1 of 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SRRK

Unlock Now

SRRK Should I Buy

SRRK Should I Buy

Should You Buy Scholar Rock Holding Corp (SRRK) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch